These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 7648835)

  • 1. National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers.
    Baron EJ; Jones RN
    Diagn Microbiol Infect Dis; 1995 Mar; 21(3):141-51. PubMed ID: 7648835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections.
    Johnson DM; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2002 May; 43(1):49-60. PubMed ID: 12052629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. A reevaluation after five years.
    Marshall SA; Aldridge KE; Allen SD; Fuchs PC; Gerlach EH; Jones RN
    Diagn Microbiol Infect Dis; 1995 Mar; 21(3):153-68. PubMed ID: 7648836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles.
    Chen HY; Bonfiglio G; Allen M; Piper D; Edwardson T; McVey D; Livermore DM
    J Antimicrob Chemother; 1993 Aug; 32(2):247-66. PubMed ID: 8226427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial gram-negative pathogens isolated from burn patients.
    Mokaddas E; Rotimi VO; Sanyal SC
    J Chemother; 1998 Jun; 10(3):208-14. PubMed ID: 9669645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of the in vitro activity of piperacillin/tazobactam.
    Daley D; Mulgrave L; Munro R; Neville S; Smith H; Dimech W
    Pathology; 1996 May; 28(2):167-72. PubMed ID: 8743825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles.
    Livermore DM; Mushtaq S; James D; Potz N; Walker RA; Charlett A; Warburton F; Johnson AP; Warner M; Henwood CJ
    Int J Antimicrob Agents; 2003 Jul; 22(1):14-27. PubMed ID: 12842324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility survey of piperacillin alone and in the presence of tazobactam.
    Acar JF; Goldstein FW; Kitzis MD
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():23-8. PubMed ID: 8383653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients.
    Casellas JM; Tomé G; Bantar C; Bertolini P; Blázquez N; Borda N; Couto E; Cudmani N; Guerrera J; Juárez MJ; López T; Littvik A; Méndez E; Notario R; Ponce G; Quinteros M; Salamone F; Sparo M; Sutich E; Vaylet S; Wolff L
    Diagn Microbiol Infect Dis; 2003 Nov; 47(3):527-37. PubMed ID: 14596972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients. Multicentre Study Group.
    Verbist L; Verhaegen J; Wouters C; Vandenhoven G
    J Antimicrob Chemother; 1996 Feb; 37(2):285-93. PubMed ID: 8707738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
    Fass RJ; Prior RB
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1268-74. PubMed ID: 2552904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results.
    Jones RN; Sutton LD; Cantrell HF; Lankford RB
    Diagn Microbiol Infect Dis; 1994 Nov; 20(3):143-9. PubMed ID: 7874881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients.
    Frank U; Mutter J; Schmidt-Eisenlohr E; Daschner FD
    Clin Microbiol Infect; 2003 Nov; 9(11):1128-32. PubMed ID: 14616732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria.
    Chang SC; Hsu LY; Luh KT; Hsieh WC
    J Formos Med Assoc; 1991 Oct; 90(10):947-52. PubMed ID: 1685175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in-vitro activity of piperacillin-tazobactam against recent clinical isolates, a Dutch national multicentre study.
    Stobberingh EE; Maclaren DM; Schmitz PI
    J Antimicrob Chemother; 1994 Nov; 34(5):777-83. PubMed ID: 7706173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activity of piperacillin/tazobactam against gram-negative bacilli.
    Liebowitz LD; Klugman KP
    S Afr Med J; 1996 Oct; 86(10):1276-80. PubMed ID: 8955735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Second multicenter study of the in vitro susceptibility to piperacillin-tazobactam].
    García-Rodríguez JA; Trujillano I;
    Rev Esp Quimioter; 2002 Jun; 15(2):169-75. PubMed ID: 12582446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.